ライフサイエンスコーパス: geographic atrophy

1 gression to late AMD (neovascular or central geographic atrophy).

2 70-1.26; P = .67) for development of central geographic atrophy.

3 ide-effects include vascular rarefaction and geographic atrophy.

4 .98 (95% CI, 0.69-1.39; P = .91) for central geographic atrophy.

5 ssociated with development or progression of geographic atrophy.

6 luding the dry type of macular degeneration, geographic atrophy.

7 gmented pattern dystrophy appears to predate geographic atrophy.

8 lsewhere, drusen, abnormal pigmentation, and geographic atrophy.

9 tinal damage and vision loss associated with geographic atrophy.

10 thesized causes are being developed to treat geographic atrophy.

11 cular AMD (choroidal neovascularization) and geographic atrophy.

12 ough index cases with neovascular disease or geographic atrophy.

13 who were 50 years or older and had bilateral geographic atrophy.

14 therapies for early and intermediate AMD and geographic atrophy.

15 for the interpretation of clinical trials in geographic atrophy.

16 etinal pigment epithelium from patients with geographic atrophy.

17 other degenerative choroidopathies, such as geographic atrophy.

18 in the absence of neovascular AMD or central geographic atrophy.

19 were elevated in the RPE in human eyes with geographic atrophy.

20 D and 14.3% (95% CI, 2.0%-42.8%; n = 2) were geographic atrophy.

21 early pseudodrusen and rapid development of geographic atrophy.

22 macular degeneration (5.2% versus 0.1%), and geographic atrophy (2.0% versus 0%).

23 es from five subjects were tested (four with geographic atrophy [66.3 +/- 6.4 years, mean +/- 1 SD] a

24 Application of BETR in patients with geographic atrophy, a disease with a known natural histo

25 In patients blinded by geographic atrophy, a subretinal photovoltaic implant wi

26 l death of the retinal pigment epithelium in geographic atrophy, a type of age-related macular degene

27 The RPE of human eyes with geographic atrophy accumulates toxic Alu RNA in response

28 Geographic atrophy affecting the fovea was thought to be

29 pigmented epithelium has been implicated in geographic atrophy, an advanced form of age-related macu

30 Geographic atrophy, an advanced form of age-related macu

31 ighly enriched in the RPE of human eyes with geographic atrophy, an untreatable form of age-related m

32 ium cells generated from 43 individuals with geographic atrophy and 36 controls with genotype data, w

33 he advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease.

34 In patients with geographic atrophy and at least 1 year of follow-up, atr

35 Areas of geographic atrophy and choroidal neovascularization imag

36 tent stem cells generated from patients with geographic atrophy and healthy individuals were differen

37 s of disease progression to be identified in geographic atrophy and may improve understanding of the

38 AMD, early AMD, intermediate AMD, late AMD, geographic atrophy and neovascular AMD were 14.1% (95% C

39 te AMD lesions, overall and specifically for geographic atrophy and neovascular AMD, compared with th

40 ng the pathogenesis of advanced AMD, in both geographic atrophy and neovascular AMD.

41 s also discriminated risk for progression to geographic atrophy and neovascular disease separately.

42 wo major AMD phenotypes (neovascular AMD and geographic atrophy) and by age of affected family member

43 tation, hypopigmentation), 5 had extrafoveal geographic atrophy, and 1 had exudative AMD.

44 727 cases of late AMD (1151 neovascular, 384 geographic atrophy, and 192 mixed [neovascular AMD and g

45 ssification of noncenter vs center-involving geographic atrophy, and area of geographic atrophy in th

46 rder of the retina, characterized by drusen, geographic atrophy, and choroidal neovascularization.

47 ween the RPE and the underlying vasculature, geographic atrophy, and choroidal neovascularization.

48 D, early AMD, intermediate AMD, or late AMD, geographic atrophy, and neovascular AMD were 18.2% (95%

49 revalence of early and advanced AMD, drusen, geographic atrophy, and neovascular AMD were determined

50 predominant phenotype based on drusen size, geographic atrophy, and neovascular AMD.

51 e size and extent of drusen, the presence of geographic atrophy, and neovascular changes.

52 or suggestively higher risk of large drusen, geographic atrophy, and neovascularization.

53 pithelium depigmentation; increased pigment; geographic atrophy; and neovascular macular degeneration

54 atrophy, and 192 mixed [neovascular AMD and geographic atrophy]) and 1153 controls.

55 ion in the retinal pigment epithelium and in geographic atrophy are identified - two of which share v

56 eting all putative phases of pathogenesis in geographic atrophy are under development.

57 12, the mean rate of square-root-transformed geographic atrophy area growth was 0.336 mm/year (SE 0.0

58 Geographic atrophy area was measured from color fundus p

59 Geographic atrophy area was measured from fundus photogr

60 btypes of late AMD (neovascular AMD and pure geographic atrophy), assessed in retinal photographs acc

61 ize ongoing and recently completed trials on geographic atrophy associated with age-related macular d

62 tivity was identified in eyes with nonfoveal geographic atrophy at both 6 months (-1.41 dB [0.22 dB];

63 , especially if therapies to slow or reverse geographic atrophy become available.

64 As a fraction of the geographic atrophy border zone, the mean new GA was 0.44

65 both advanced types of AMD (neovasuclar and geographic atrophy both present) using multimodal imagin

66 gment epithelial atrophy preceded CC loss in geographic atrophy, but CC loss occurred in the absence

67 ks of developing neovascular AMD and central geographic atrophy by 10 years were 48.1% and 26.0%, res

68 h a reduced likelihood of developing central geographic atrophy (CGA) and neovascular (NV) AMD.

69 NRTIs were efficacious in mouse models of geographic atrophy, choroidal neovascularization, graft-

70 A novel parameter called the "Geographic Atrophy Circularity Index" (GACI) was develop

71 Geographic atrophy confounds automated segmentation in a

72 All participants in whom geographic atrophy developed during follow-up had visibl

73 Geographic atrophy developed in 5% of eyes at 2 years an

74 At 2 years, geographic atrophy developed in a lower percentage of ey

75 ion of Bruch membrane alterations to CNV and geographic atrophy development in age-related macular de

76 ty, thickness, and gap length in donors with geographic atrophy did not differ from those of controls

77 Geographic atrophy due to age-related macular degenerati

78 In this study involving 38 participants with geographic atrophy due to AMD, the PRIMA system restored

79 ipants had intermediate AMD, 8 had nonfoveal geographic atrophy due to AMD.

80 Geographic atrophy enlarged in each eye over time.

81 Geographic atrophy enlargement in these eyes was signifi

82 Geographic atrophy enlargement in these eyes was similar

83 Geographic atrophy enlargement is faster in eyes with RP

84 Geographic atrophy enlargement was significantly faster

85 Geographic atrophy enlargement was significantly faster

86 Geographic atrophy evolving from minimal change autofluo

87 was defined as newly diagnosed advanced AMD (geographic atrophy, exudative disease, or AMD causing vi

88 fibrosis, pigment epithelium detachment, and geographic atrophy/fibrotic scar/neovascular AMD in the

89 images were semiautomatically annotated for geographic atrophy, followed by extraction of shape-desc

90 otoreceptor cell loss in late AMD, including geographic atrophy, for which no efficient treatment cur

91 Geographic atrophy foveal involvement and focality corre

92 anatomically with the site at which areolar (geographic) atrophy frequently occurs in retinal pigment

93 re scarring (60.0% vs 41.4%, P = .007), more geographic atrophy (GA) (31.6% vs 20.7%, P = .004), larg

94 ociations between the complement pathway and geographic atrophy (GA) (OR, 2.17; 95% CI, 1.12-4.24; P

95 Early stages of geographic atrophy (GA) age-related macular degeneration

96 either choroidal neovascularization (CNV) or geographic atrophy (GA) and 53 donor eyes of 53 patients

97 orrelations among enlargement rates (ERs) of geographic atrophy (GA) and choriocapillaris (CC) flow d

98 CVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization

99 The right eye in case 1 had geographic atrophy (GA) and demonstrated a large area in

100 n focally increased autofluorescence (FIAF), geographic atrophy (GA) and focally decreased autofluore

101 on: No AMD, Intermediate AMD, and Late AMD - geographic atrophy (GA) and Late AMD - neovascular (NV).

102 d to evaluate progression rates to late AMD: geographic atrophy (GA) and neovascular (NV)-AMD.

103 a on age-sex-specific incidence of late AMD, geographic atrophy (GA) and neovascular AMD (NVAMD), yea

104 types of advanced AMD pathologies, including geographic atrophy (GA) and neovascular pathologies, wer

105 These changes are reminiscent of geographic atrophy (GA) and point to a role for RPE-deri

106 To correlate the area of geographic atrophy (GA) and residual foveal sparing (FS)

107 AMD is clinically heterogeneous, leading to geographic atrophy (GA) and/or choroidal neovascularizat

108 but risk factors for rapid 15-letter loss in geographic atrophy (GA) are poorly understood.

109 n the 4-step scale, while depigmentation and geographic atrophy (GA) areas correlated with advanced A

110 GA for the conventional clinical endpoint of geographic atrophy (GA) as defined on color fundus photo

111 Eyes with geographic atrophy (GA) at 2 years were correlated with

112 verity scale after 2 updates: (1) noncentral geographic atrophy (GA) considered part of the outcome,

113 the genetic risk factors that contribute to geographic atrophy (GA) could lead to advancements in in

114 mate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up amon

115 Existing therapies to slow geographic atrophy (GA) enlargement in age-related macul

116 Investigate associations between geographic atrophy (GA) growth rate and multimodal imagi

117 studies of fundus autofluorescence (FAF) in geographic atrophy (GA) have been nonquantitative, with

118 rogression or development of junctional zone geographic atrophy (GA) in age-related macular degenerat

119 hod useful for estimating the progression of geographic atrophy (GA) in clinical trials.

120 as the new appearance of neovascular AMD or geographic atrophy (GA) in eyes at risk of late AMD.

121 ctors, incidence, and rate of progression of geographic atrophy (GA) in eyes with neovascular age-rel

122 Geographic atrophy (GA) in the fellow eye was associated

123 Geographic atrophy (GA) is a vision-threatening manifest

124 Geographic atrophy (GA) is an advanced form of age-relat

125 Geographic atrophy (GA) is an advanced form of dry age-r

126 ying degrees with anti-angiogenic drugs, but geographic atrophy (GA) is an advanced stage of the more

127 No effective therapeutic strategy for geographic atrophy (GA) is available, and prevention cou

128 Geographic atrophy (GA) is characterized by the loss of

129 Geographic atrophy (GA) is the end-stage manifestation o

130 Geographic atrophy (GA) is the major cause of blind regi

131 as a targeted psychometric testing method in geographic atrophy (GA) is warranted because of the dise

132 ors injections (IVCIs) slowed progression of geographic atrophy (GA) lesions in several registration

133 ter retinal atrophy (iRORA) within eyes with geographic atrophy (GA) might reflect similar changes am

134 Geographic atrophy (GA) of AMD and Stargardt atrophy are

135 Progressive geographic atrophy (GA) of the retinal pigment epitheliu

136 Appearance of geographic atrophy (GA) on color photography (CP) is pre

137 e drusen substructures independently predict geographic atrophy (GA) onset secondary to age-related m

138 Development of late AMD, defined as geographic atrophy (GA) or neovascular AMD (NVAMD), was

139 epithelium (RPE) defects not attributable to geographic atrophy (GA) or RPE-tears with overlying pres

140 (VA), disease progression and vision loss in geographic atrophy (GA) owing to AMD are gradual process

141 AP) study was designed to assess the rate of geographic atrophy (GA) progression and to identify prog

142 a healthy normal eye as well as of eyes with geographic atrophy (GA) secondary to age-related macular

143 ents (n = 71) 50 years of age and older with geographic atrophy (GA) secondary to age-related macular

144 al integrity and slow disease progression in geographic atrophy (GA) secondary to age-related macular

145 Geographic atrophy (GA) secondary to age-related macular

146 es of adults aged >/=50 years with bilateral geographic atrophy (GA) secondary to age-related macular

147 nhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study)

148 atural history of unifocal versus multifocal geographic atrophy (GA) secondary to nonexudative age-re

149 escent choroidal neovascularization (CNV) in geographic atrophy (GA) secondary to nonexudative age-re

150 D show accumulation of dsRNA, peaking at the geographic atrophy (GA) stage.

151 ce (SS) OCT scan patterns were used to image geographic atrophy (GA) to determine if they provided si

152 nd eventually to neovascular disease (NV) or geographic atrophy (GA) was applied to estimate stage-sp

153 Presence of geographic atrophy (GA) was associated with the highest

154 Geographic atrophy (GA) was associated with worse VA (64

155 ges of choroidal neovascularization (CNV) or geographic atrophy (GA) was evaluated to determine wheth

156 lar degeneration (AMD) and advanced AMD with geographic atrophy (GA) were assayed for AGE and RAGE by

157 In zones 2 and 3, neovascularization and geographic atrophy (GA) were present, ranging from 0.4%

158 od standard for assessing dry AMD late-stage geographic atrophy (GA) while OCT has been used for asse

159 Geographic atrophy (GA), a late stage of age-related mac

160 of the retinal pigmented epithelium (RPE) in geographic atrophy (GA), a late stage of age-related mac

161 The cause of geographic atrophy (GA), a progressive dry form of age-r

162 pigmented epithelium (RPE) is implicated in geographic atrophy (GA), an advanced form of age-related

163 Geographic atrophy (GA), an untreatable advanced form of

164 lateral large, soft drusen, with and without geographic atrophy (GA), and 55 fellow eyes of 55 patien

165 color photographs, including drusen volume, geographic atrophy (GA), and preatrophic features, were

166 ee aged control subjects, five subjects with geographic atrophy (GA), and three subjects with wet AMD

167 s with both choroidal neovascularization and geographic atrophy (GA), but few genome-wide scans (GWSs

168 enotypes of choroidal neovascularization and geographic atrophy (GA), identified variants in DMD asso

169 y age-related macular degeneration (AMD), or geographic atrophy (GA), is characterized by extensive r

170 as 8.4%; for late AMD, it was 1.4%; for pure geographic atrophy (GA), it was 0.6%; for exudative AMD,

171 rs to reliably identify precursor lesions to geographic atrophy (GA), known as persistent choroidal h

172 e dry AMD (AREDS stage 3), advanced AMD with geographic atrophy (GA), or neovascular AMD (CNV).

173 m the mean as abnormal, indicating drusen or geographic atrophy (GA), respectively.

174 phy growth rate in treatment-naive eyes with geographic atrophy (GA), Stargardt disease (STGD1), Best

175 Geographic atrophy (GA), the non-neovascular advanced fo

176 and safety of oral ALA for the treatment of geographic atrophy (GA).

177 ry age-related macular degeneration (AMD) or geographic atrophy (GA).

178 ies in SD-OCT images of eyes with drusen and geographic atrophy (GA).

179 ive MNV may slow down the growth of adjacent geographic atrophy (GA).

180 eye status predicts the progression rate of geographic atrophy (GA).

181 s at baseline predict annual growth rates of geographic atrophy (GA).

182 ond treatment, and 7/234 patients (3.0%) had geographic atrophy (GA).

183 ation 4 included neovascular AMD (nvAMD) and geographic atrophy (GA).

184 a 77-year-old nonexudative AMD patient with geographic atrophy (GA).

185 ) of atrophic zones (AZ), which characterize geographic atrophy (GA).

186 y of late, nonexudative AMD is the growth of geographic atrophy (GA).

187 lial growth factor (anti-VEGF) treatments or geographic atrophy (GA).

188 pment of late AMD, either neovascular AMD or geographic atrophy (GA).

189 61 for CNV, fluid, or hemorrhage; 65 for non-geographic atrophy (GA); 64 for nonfibrotic scar; 53 for

190 on, acquired vitelliform lesions (AVLs), and geographic atrophy (GA); and ultrastructural and stainin

191 mined predominant presence of the following: geographic atrophy (GA, n = 25), non-GA (NGA, n = 44), f

192 y AMD (n = 35), or clinically diagnosed with geographic atrophy (GA; n = 9, collected from outside th

193 ne, 22.7% progressed to late AMD (11.0% pure geographic atrophy [GA] and 11.7% exudative AMD).

194 +/- 21.18 um) groups (among which eyes with geographic atrophy [GA] had the lowest thickness, of 58.

195 Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either ey

196 pment of late AMD (neovascular AMD [nAMD] or geographic atrophy [GA]) or large drusen.

197 severity groups (from controls to non-foveal geographic atrophy [GA]), and the relationships and magn

198 Geographic atrophy growth depends on several ocular fact

199 Geographic atrophy growth rate showed a weak correlation

200 , recruitment completed), five patients with geographic atrophy have been implanted with a wireless 2

201 68.4 for nongeographic atrophy; and 62.9 for geographic atrophy, hemorrhage, RPE tear, or scar (P < 0

202 0 [95% CI, 1.20-4.15]; P = .01) but not pure geographic atrophy (HR, 0.66 [95% CI, 0.25-1.95]; P = .4

203 OSA were associated with an elevated risk of geographic atrophy (HR, 7.00; 95% CI, 4.47-11.0; P = 0.0

204 um (RPE) atrophy/absence in 22.9%, subfoveal geographic atrophy in 2.5%, and fluid in or under the re

205 um detachment (DPED) is a known precursor to geographic atrophy in age-related macular degeneration (

206 ntiated umbilical cells for the treatment of geographic atrophy in age-related macular degeneration.

207 ational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration.

208 gents are under development for treatment of geographic atrophy in both pre and early-phase clinical

209 obtaining an accurate timeline of incipient geographic atrophy in clinic populations and for quantif

210 lysis, best-corrected visual acuity, area of geographic atrophy in the central Early Treatment Diabet

211 Geographic atrophy in the fellow eye, hemorrhage, and ab

212 er-involving geographic atrophy, and area of geographic atrophy in the inner-right ETDRS subfield sho

213 rected visual acuity, drusen progression, or geographic atrophy in the study eye were observed throug

214 macular degeneration (neovascular or central geographic atrophy) in one eye should consider taking th

215 Geographic atrophy incidence and growth rate.

216 Isolated geographic atrophy independent of CNV can develop in pse

217 Eight eyes (20%) of 5 patients had geographic atrophy independent of CNV.

218 Geographic atrophy is a blinding form of age-related mac

219 Geographic atrophy is a leading cause of progressive, ir

220 Geographic atrophy is an advanced form of dry age-relate

221 Geographic atrophy is defined by the presence of sharply

222 oplan every other month significantly slowed geographic atrophy lesion growth by 21% (absolute differ

223 y and pegcetacoplan every other month slowed geographic atrophy lesion growth by 22% (-0.90 mm(2), -1

224 Geographic atrophy lesion growth rate was similar among

225 y and pegcetacoplan every other month slowed geographic atrophy lesion growth, although it did not re

226 Geographic atrophy lesion size increased from 8.88 mm(2)

227 uantification paves the way toward optimized geographic atrophy management.

228 Geographic atrophy may be detected earlier by the use of

229 Areas of interest in patients with geographic atrophy measured from baseline to month 12 by

230 elA inhibition in an oxidative stress-driven geographic atrophy mouse model.

231 ers (95% CI, 6.7-10.7), eyes with noncentral geographic atrophy (n = 70) gained 8.9 letters (95% CI,

232 mediate (n = 5), and advanced stages of AMD (geographic atrophy, n = 5; neovascular disease, n = 13)

233 ion loss included older age, worse index VA, geographic atrophy (nAMD), and worsening baseline diabet

234 classified into early AMD, intermediate AMD, geographic atrophy, neovascular AMD, or both advanced ty

235 8-12.1), and eyes with advanced AMD (central geographic atrophy, neovascular disease, or both; n = 32

236 Nascent geographic atrophy (nGA) describes features on OCT imagi

237 omography (OCT) imaging can identify nascent geographic atrophy (nGA) in eyes with intermediate age-r

238 These characteristics were termed "nascent geographic atrophy" (nGA), describing features that port

239 of BBBD therapy, progressive enlargement of geographic atrophy occurred in 5 eyes of 3 patients, and

240 opathy progression, including enlargement of geographic atrophy, occurred years after completion of s

241 and concomitant vision loss associated with geographic atrophy of the macula.

242 patients with EODM (44.9%) were affected by geographic atrophy or choroidal neovascularization.

243 at the 5-year follow-up examination of pure geographic atrophy or exudative macular degeneration, an

244 Analysis of the combined geographic atrophy or neovascular AMD cases in the NEI,

245 Late AMD was defined as the presence of geographic atrophy or neovascular AMD detected on annual

246 RPE of eyes affected by geographic atrophy or neovascular AMD exhibited NLRP3 st

247 an ocular tissue sections from patients with geographic atrophy or neovascular AMD were stained for N

248 graded for development of late AMD (central geographic atrophy or neovascular AMD) or pseudophakia.

249 rmediate disease, and 222 with advanced AMD (geographic atrophy or neovascular AMD).

250 Late ARM was defined as presence of either geographic atrophy or neovascular ARM.

251 ls, of which 279 progressed to advanced AMD (geographic atrophy or neovascular disease) and 1167 did

252 of whom 294 progressed to advanced stages of geographic atrophy or neovascular disease.

253 a-analyses were subgrouped by progression to geographic atrophy or neovascularization.

254 retinal tissue complex on OCT, and subfoveal geographic atrophy or scar on FP/FA had the worst VA.

255 ssociated with the 10-year incidence of pure geographic atrophy (OR per 0.1 mm IMT, 1.31; CI, 1.05-1.

256 , 0.90-2.48 and 1.39-4.90, respectively) and geographic atrophy (OR, 2.57 and 4.52; 95% CI, 0.99-6.71

257 se (OR, 6.1; 95% CI, 3.3-11.2) compared with geographic atrophy (OR, 3.0; 95% CI, 1.4-6.5) relative t

258 mediate AMD), grade 4 (central or noncentral geographic atrophy), or grade 5 (neovascular disease).

259 nsive intermediate drusen, any large drusen, geographic atrophy, or evidence of exudative maculopathy

260 e-8 expression in the RPE of human eyes with geographic atrophy, our findings provide a rationale for

261 as associated more frequently with patchy or geographic atrophy (P = .019).

262 r neovascularization (P = 0.042) but not for geographic atrophy (P = 0.47).

263 As knowledge of geographic atrophy pathophysiology advances, targeted ph

264 a 49% increase in the risk of advanced AMD (geographic atrophy plus neovascularization) for persons

265 Geographic atrophy presented as a single lesion in 89 (7

266 The Geographic Atrophy Progression (GAP) study was designed

267 Geographic atrophy progression is faster in women, but i

268 Main outcome measures included incidence of geographic atrophy, progression over time, and macular f

269 VA; scar; geographic atrophy; retinal thickness, fluid; and number

270 ening in the SCOPE natural history study for geographic atrophy secondary to age-related macular dege

271 As a disabling and frequent disease, geographic atrophy secondary to age-related macular dege

272 IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular dege

273 Of these 38 eyes, 23 (60%) had geographic atrophy secondary to age-related macular dege

274 clinical investigation for the treatment of geographic atrophy secondary to age-related macular dege

275 graphic Atrophy study included patients with geographic atrophy secondary to AMD who were recruited a

276 cular degeneration (AMD) and 2 eyes (5%) had geographic atrophy secondary to pattern dystrophy.

277 h lesions associated with neovascular AMD or geographic atrophy should be considered to have late AMD

278 ective natural history Directional Spread in Geographic Atrophy study included patients with geograph

279 Europeans had a higher prevalence of geographic atrophy subtype (1.11%, 95% CrI 0.53-2.08) th

280 Geographic atrophy that formed in areas previously occup

281 Geographic atrophy, the advanced form of age-related mac

282 in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition cha

283 oroidal neovascularization area, presence of geographic atrophy, total foveal thickness </=325 mum or

284 ial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Rela

285 ial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Rela

286 ere stratified by AMD severity (early versus geographic atrophy versus neovascular), the inverse asso

287 homozygous carriers, the odds ratio (OR) of geographic atrophy was 8.6 (95% confidence interval [CI]

288 Geographic atrophy was also automatically delineated usi

289 Geographic atrophy was defined according to the Revised

290 mum were found in 24.1% (95% CI, 22.5-25.8), geographic atrophy was found in 1.0% of participants (95

291 Geographic atrophy was measured on blue autofluorescence

292 A higher prevalence of geographic atrophy was observed among patients carrying

293 Geographic atrophy was present in 213 of 515 (41%) grada

294 ction threshold of the eyes with extrafoveal geographic atrophy was significantly higher than that of

295 eater outer retinal thickness, and decreased geographic atrophy were associated with increased BCVA g

296 nd experts, choroidal neovascularization and geographic atrophy were found to be important biomarkers

297 However, persons who had geographic atrophy were more likely to have large drusen

298 ly AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), a

299 and advanced AMD (neovascular AMD or central geographic atrophy) were evaluated using annual fundus p

300 Six patients with bilateral geographic atrophy who were using an eccentrically locat